Terms: = Colorectal cancer AND RNF43, DKFZp781H02126, 54894, Q68DV7, URCC, RNF124, MGC125630, FLJ20315, DKFZp781H0392
118 results:
1. Novel drug resistance mechanisms and drug targets in BRAF-mutated peritoneal metastasis from colorectal cancer.
Lund-Andersen C; Torgunrud A; Kanduri C; Dagenborg VJ; Frøysnes IS; Larsen MM; Davidson B; Larsen SG; Flatmark K
J Transl Med; 2024 Jul; 22(1):646. PubMed ID: 38982444
[TBL] [Abstract] [Full Text] [Related]
2. Molecular profiling of pediatric and young adult colorectal cancer reveals a distinct genomic landscapes and potential therapeutic avenues.
Busico A; Gasparini P; Rausa E; Cattaneo L; Bozzi F; Silvestri M; Capone I; Conca E; Tamborini E; Perrone F; Vitellaro M; Ricci MT; Casanova M; Chiaravalli S; Bergamaschi L; Massimino M; Milione M; Sozzi G; Pruneri G; Ferrari A; Signoroni S
Sci Rep; 2024 Jun; 14(1):13138. PubMed ID: 38849509
[TBL] [Abstract] [Full Text] [Related]
3. Mucin phenotype and genetic alterations in non-V600E BRAF-mutated colorectal cancer.
Ozeki H; Shimada Y; Nakano M; Kondo S; Ohashi R; Miwa Y; Yamai D; Matsumoto A; Abe K; Tajima Y; Ichikawa H; Sakata J; Takii Y; Sugai M; Nagai T; Ling Y; Okuda S; Wakai T
Hum Pathol; 2024 Mar; 145():71-79. PubMed ID: 38423222
[TBL] [Abstract] [Full Text] [Related]
4. Association of rnf43 Genetic Alterations With BRAF
Vogel A; Murugesan K; Kendre G; Quintanilha JCF; Ross JS; Brummer T; Saborowski A
JCO Precis Oncol; 2024 Feb; 8():e2300411. PubMed ID: 38394466
[TBL] [Abstract] [Full Text] [Related]
5. Inherited BRCA1 and rnf43 pathogenic variants in a familial colorectal cancer type X family.
Chan JM; Clendenning M; Joseland S; Georgeson P; Mahmood K; Joo JE; Walker R; Como J; Preston S; Chai SM; Chu YL; Meyers AL; Pope BJ; Duggan D; Fink JL; Macrae FA; Rosty C; Winship IM; Jenkins MA; Buchanan DD
Fam Cancer; 2024 Mar; 23(1):9-21. PubMed ID: 38063999
[TBL] [Abstract] [Full Text] [Related]
6. DNA Mutational Profiling in Patients With colorectal cancer Treated With Standard of Care Reveals Differences in Outcome and Racial Distribution of Mutations.
Innocenti F; Mu W; Qu X; Ou FS; Kabbarah O; Blanke CD; Venook AP; Lenz HJ; Rashid NU
J Clin Oncol; 2024 Feb; 42(4):399-409. PubMed ID: 37992266
[TBL] [Abstract] [Full Text] [Related]
7. [Comprehensive assessment of mismatch repair and microsatellite instability status in molecular classification of endometrial carcinoma].
Liu Y; Wang YX; Sun XJ; Ting X; Wu R; Liu XD; Liu CR
Zhonghua Fu Chan Ke Za Zhi; 2023 Oct; 58(10):755-765. PubMed ID: 37849256
[No Abstract] [Full Text] [Related]
8. Predictive Impact of
Moretto R; Germani MM; Ros J; Daniel F; Ghelardi F; Vetere G; Giordano M; Toledo RA; Bergamo F; Randon G; Elez E; Lonardi S; Pietrantonio F; Vignali P; Rossini D; Matito J; Ugolini C; Fontanini G; Masi G; Cremolini C
JCO Precis Oncol; 2023 Sep; 7():e2300255. PubMed ID: 37797285
[TBL] [Abstract] [Full Text] [Related]
9. Treatment of
Ros J; Rodríguez-Castells M; Saoudi N; Baraibar I; Salva F; Tabernero J; Élez E
Expert Rev Anticancer Ther; 2023; 23(8):797-806. PubMed ID: 37482749
[TBL] [Abstract] [Full Text] [Related]
10. Genomic landscape and its prognostic significance in stage III colorectal cancer: JCOG1506A1, an ancillary of JCOG0910.
Shida D; Kuchiba A; Shibata T; Hamaguchi T; Yamasaki S; Ito M; Kobatake T; Tonooka T; Masaki T; Shiozawa M; Takii Y; Uetake H; Okamura S; Ojima H; Kazama S; Takeyama H; Kanato K; Shimada Y; Murakami Y; Kanemitsu Y
Cancer Sci; 2023 Aug; 114(8):3352-3363. PubMed ID: 37189003
[TBL] [Abstract] [Full Text] [Related]
11. Genomically matched therapy in refractory colorectal cancer according to ESMO Scale for Clinical Actionability of Molecular Targets: experience of a comprehensive cancer centre network.
Mulet Margalef N; Castillo C; Mosteiro M; Pérez X; Aguilar S; Ruíz-Pace F; Gil M; Cuadra C; Ruffinelli JC; Martínez M; Losa F; Soler G; Teulé À; Castany R; Gallego R; Ruíz A; Garralda E; Élez E; Vivancos A; Tabernero J; Salazar R; Dienstmann R; Santos Vivas C
Mol Oncol; 2023 Sep; 17(9):1908-1916. PubMed ID: 37097008
[TBL] [Abstract] [Full Text] [Related]
12. Differences in DNA damage repair gene mutations between left- and right-sided colorectal cancer.
Huang W; Li W; Xu N; Li H; Zhang Z; Zhang X; He T; Yao J; Xu M; He Q; Guo L; Zhang S
Cancer Med; 2023 May; 12(9):10187-10198. PubMed ID: 37096801
[TBL] [Abstract] [Full Text] [Related]
13. The Wnt Pathway Inhibitor RXC004 Blocks Tumor Growth and Reverses Immune Evasion in Wnt Ligand-dependent cancer Models.
Phillips C; Bhamra I; Eagle C; Flanagan E; Armer R; Jones CD; Bingham M; Calcraft P; Edmenson Cook A; Thompson B; Woodcock SA
Cancer Res Commun; 2022 Sep; 2(9):914-928. PubMed ID: 36922934
[TBL] [Abstract] [Full Text] [Related]
14. A Phase Ib/II Study of WNT974 + Encorafenib + Cetuximab in Patients With BRAF V600E-Mutant KRAS Wild-Type Metastatic colorectal cancer.
Tabernero J; Van Cutsem E; Garralda E; Tai D; De Braud F; Geva R; van Bussel MTJ; Fiorella Dotti K; Elez E; de Miguel MJ; Litwiler K; Murphy D; Edwards M; Morris VK
Oncologist; 2023 Mar; 28(3):230-238. PubMed ID: 36811382
[TBL] [Abstract] [Full Text] [Related]
15. BRAF V600E and rnf43 Co-mutations Predict Patient Outcomes With Targeted Therapies in Real-World Cases of colorectal cancer.
Quintanilha JCF; Graf RP; Oxnard GR
Oncologist; 2023 Mar; 28(3):e171-e174. PubMed ID: 36779536
[TBL] [Abstract] [Full Text] [Related]
16. Genetic Predisposition to colorectal cancer: How Many and Which Genes to Test?
Rebuzzi F; Ulivi P; Tedaldi G
Int J Mol Sci; 2023 Jan; 24(3):. PubMed ID: 36768460
[TBL] [Abstract] [Full Text] [Related]
17. Somatic mutations can induce a noninflamed tumour microenvironment via their original gene functions, despite deriving neoantigens.
Ishino T; Kawashima S; Tanji E; Ueno T; Ueda Y; Ogasawara S; Sato K; Mano H; Ishihara S; Kato N; Kawazu M; Togashi Y
Br J Cancer; 2023 Apr; 128(6):1166-1175. PubMed ID: 36732592
[TBL] [Abstract] [Full Text] [Related]
18. Racial/Ethnic and Sex Differences in Somatic cancer Gene Mutations among Patients with Early-Onset colorectal cancer.
Holowatyj AN; Wen W; Gibbs T; Seagle HM; Keller SR; Edwards DRV; Washington MK; Eng C; Perea J; Zheng W; Guo X
Cancer Discov; 2023 Mar; 13(3):570-579. PubMed ID: 36520636
[TBL] [Abstract] [Full Text] [Related]
19. Cartilage oligomeric matrix protein acts as a molecular biomarker in multiple cancer types.
Guo B; Wang Y; Liu W; Zhang S
Clin Transl Oncol; 2023 Feb; 25(2):535-554. PubMed ID: 36255654
[TBL] [Abstract] [Full Text] [Related]
20. Monitoring tumour resistance to the BRAF inhibitor combination regimen in colorectal cancer patients via circulating tumour DNA.
Ye LF; Huang ZY; Chen XX; Chen ZG; Wu SX; Ren C; Hu MT; Bao H; Jin Y; Wang F; Wang FH; Du ZM; Wu X; Ju HQ; Shao Y; Li YH; Xu RH; Wang DS
Drug Resist Updat; 2022 Dec; 65():100883. PubMed ID: 36202008
[TBL] [Abstract] [Full Text] [Related]
[Next]
